Search Results

There are 65937 results for: content related to: Natalizumab effects on immune cell responses in multiple sclerosis

  1. You have free access to this content
    Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory Diseases

    CNS Drug Reviews

    Volume 13, Issue 1, March 2007, Pages: 79–95, Olaf Stüve and Jeffrey L. Bennett

    Version of Record online : 24 APR 2007, DOI: 10.1111/j.1527-3458.2007.00003.x

  2. VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow

    British Journal of Haematology

    Volume 174, Issue 6, September 2016, Pages: 970–982, Jennell White, Sriram Krishnamoorthy, Dipti Gupta, Moira Lancelot, Nancy Moore, Sharada Sarnaik, William E. Hobbs II, David R. Light and Patrick Hines

    Version of Record online : 12 JUN 2016, DOI: 10.1111/bjh.14158

  3. You have free access to this content
    Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance

    British Journal of Haematology

    Volume 155, Issue 1, October 2011, Pages: 53–64, Marek Mraz, Clive S. Zent, Amy K. Church, Diane F. Jelinek, Xiaosheng Wu, Sarka Pospisilova, Stephen M. Ansell, Anne J. Novak, Neil E. Kay, Thomas E. Witzig and Grzegorz S. Nowakowski

    Version of Record online : 12 JUL 2011, DOI: 10.1111/j.1365-2141.2011.08794.x

  4. Therapeutic interference with leukocyte recirculation in multiple sclerosis

    European Journal of Neurology

    Volume 22, Issue 3, March 2015, Pages: 434–442, F. Sellebjerg and P. S. Sørensen

    Version of Record online : 13 JAN 2015, DOI: 10.1111/ene.12668

  5. You have full text access to this OnlineOpen article
    B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity

    Annals of Neurology

    Volume 77, Issue 5, May 2015, Pages: 902–908, Klaus Lehmann-Horn, Sharon A. Sagan, Claude C.A. Bernard, Raymond A. Sobel and Scott S. Zamvil

    Version of Record online : 28 MAR 2015, DOI: 10.1002/ana.24387

  6. You have free access to this content
    Molecular targeted therapy against the blood–brain barrier in multiple sclerosis

    Clinical and Experimental Neuroimmunology

    Volume 5, Issue s1, December 2014, Pages: 28–34, Takashi Kanda

    Version of Record online : 18 DEC 2014, DOI: 10.1111/cen3.12167

  7. You have full text access to this OnlineOpen article
    Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 1, January 2015, Pages: 43–55, Jens Ingwersen, Til Menge, Britta Wingerath, Derya Kaya, Jonas Graf, Tim Prozorovski, Andreas Keller, Christina Backes, Markus Beier, Matthias Scheffler, Thomas Dehmel, Bernd C. Kieseier, Hans-Peter Hartung, Patrick Küry and Orhan Aktas

    Version of Record online : 5 DEC 2014, DOI: 10.1002/acn3.152

  8. You have free access to this content
    Blood–brain barrier: A novel therapeutic target in multiple sclerosis

    Clinical and Experimental Neuroimmunology

    Volume 6, Issue 2, May 2015, Pages: 129–138, Hiroya Kuwahara, Kazutaka Nishina and Takanori Yokota

    Version of Record online : 19 APR 2015, DOI: 10.1111/cen3.12212

  9. You have free access to this content
    The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

    British Journal of Haematology

    Volume 155, Issue 4, November 2011, Pages: 438–448, Klaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, Giovanni Tonon, Ursula Hainz, Yu-Tzu Tai, Sonia Vallet, Niels Halama, Dirk Jäger, Dian L. Olson, Martin Sattler, Dharminder Chauhan and Kenneth C. Anderson

    Version of Record online : 19 SEP 2011, DOI: 10.1111/j.1365-2141.2011.08864.x

  10. You have free access to this content
    High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis

    Clinical & Experimental Immunology

    Volume 180, Issue 3, June 2015, Pages: 383–392, A. Harrer, G. Pilz, P. Wipfler, K. Oppermann, J. Sellner, W. Hitzl, E. Haschke-Becher, S. Afazel, T. Rispens, D. van der Kleij, E. Trinka and J. Kraus

    Version of Record online : 27 APR 2015, DOI: 10.1111/cei.12590

  11. Modulation of Experimental Autoimmune Encephalomyelitis by VLA-2 Blockade

    Brain Pathology

    Volume 17, Issue 1, January 2007, Pages: 45–55, Ikuo Tsunoda, Emily Jane Terry, Benjamin J. Marble, Elias Lazarides, Catherine Woods and Robert S. Fujinami

    Version of Record online : 22 JAN 2007, DOI: 10.1111/j.1750-3639.2006.00042.x

  12. You have free access to this content
    Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets

    British Journal of Pharmacology

    Volume 166, Issue 3, June 2012, Pages: 823–846, Peter J Bugelski and Pauline L Martin

    Version of Record online : 8 MAY 2012, DOI: 10.1111/j.1476-5381.2011.01811.x

  13. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers

    European Journal of Neurology

    Volume 16, Issue 4, April 2009, Pages: 528–536, M. Khademi, L. Bornsen, F. Rafatnia, M. Andersson, L. Brundin, F. Piehl, F. Sellebjerg and T. Olsson

    Version of Record online : 11 FEB 2009, DOI: 10.1111/j.1468-1331.2009.02532.x

  14. You have free access to this content
    Monoclonal antibodies in treatment of multiple sclerosis

    Clinical & Experimental Immunology

    Volume 175, Issue 3, March 2014, Pages: 373–384, P. S. Rommer, A. Dudesek, O. Stüve and U.K. Zettl

    Version of Record online : 4 FEB 2014, DOI: 10.1111/cei.12197

  15. Natalizumab (Tysabri)

    Handbook of Therapeutic Antibodies

    Sebastian Schimrigk, Ralf Gold, Pages: 941–950, 2008

    Published Online : 1 FEB 2008, DOI: 10.1002/9783527619740.ch36

  16. You have free access to this content
    Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)

    British Journal of Pharmacology

    Volume 164, Issue 4, October 2011, Pages: 1079–1106, Cris S Constantinescu, Nasr Farooqi, Kate O'Brien and Bruno Gran

    Version of Record online : 26 SEP 2011, DOI: 10.1111/j.1476-5381.2011.01302.x

  17. You have free access to this content
    Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab

    Clinical & Experimental Immunology

    Volume 176, Issue 3, June 2014, Pages: 320–326, T. Koudriavtseva, E. Sbardella, E. Trento, V. Bordignon, G. D'Agosto and P. Cordiali-Fei

    Version of Record online : 24 APR 2014, DOI: 10.1111/cei.12261

  18. Immune surveillance in multiple sclerosis patients treated with natalizumab

    Annals of Neurology

    Volume 59, Issue 5, May 2006, Pages: 743–747, Olaf Stüve, Christina M. Marra, Keith R. Jerome, Linda Cook, Petra D. Cravens, Sabine Cepok, Elliot M. Frohman, J. Theodore Phillips, Gabriele Arendt, Bernhard Hemmer, Nancy L. Monson and Michael K. Racke

    Version of Record online : 21 APR 2006, DOI: 10.1002/ana.20858

  19. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 86, Issue 2, April 2009, Pages: 117–130, Nancy G. Wehner, George Shopp, Satoru Oneda and Janet Clarke

    Version of Record online : 10 MAR 2009, DOI: 10.1002/bdrb.20190

  20. Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model

    Neuropathology and Applied Neurobiology

    Volume 41, Issue 6, October 2015, Pages: 814–831, Darius Häusler, Stefan Nessler, Niels Kruse, Wolfgang Brück and Imke Metz

    Version of Record online : 2 MAY 2015, DOI: 10.1111/nan.12220